Current status of acute intravenous therapy for chronic heart failure exacerbations

Keyphrases

• Chronic Heart Failure 100%
• Heart Failure Exacerbation 100%
• Intravenous Therapy 100%
• Heart Failure 50%
• Hospitalization 50%
• Developmental Stages 50%
• Vasodilator 50%
• Randomized Placebo-controlled Trial 50%
• Heart Failure Management 50%
• Heart Failure Readmission 50%
• Readmission Rates 50%
• Acute Decompensated Heart Failure 50%
• Diuretics 50%
• New Agents 50%
• Total Mortality 50%
• Beta-blockers 50%
• Vasoreactivity 50%
• Disease Groups 50%
• ACE Inhibitors 50%
• Vasopressin Receptor Antagonists 50%
• Intravenous Agents 50%
• Hospital Days 50%
• Inotropic Agents 50%
• Natriuretic Peptides 50%
• Inpatient Therapy 50%
• Antagonist Peptide 50%

Medicine and Dentistry

• Intravenous Drug Administration 100%
• Congestive Heart Failure 100%
• Diseases 28%
• Vasodilator Agent 28%
• Isotopes of Calcium 14%
• ACE Inhibitor 14%
• Diuretic Agent 14%
• Inotropic Agent 14%
• Vasopressin Receptor Antagonist 14%
• Natriuretic Factor 14%
• Placebo 14%
• Developmental Stage 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Intravenous Therapy 100%
• Congestive Heart Failure 100%
• Vasodilator Agent 28%
• Disease 28%
• Placebo 14%
• Diuretic Agent 14%
• Dipeptidyl Carboxypeptidase Inhibitor 14%
• Inotropic Agent 14%
• Natriuretic Factor 14%
• Vasopressin Receptor Antagonist 14%